Factor XIII Deficiency

A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency

NCT00883090 | PHASE 2 | INTERVENTIONAL

Congenital deficiency of Factor XIII is an extremely rare hereditary disorder associated with potentially life-threatening bleeding. This study will evaluate the safety and recommended (best) amount or level of Factor XIII in a patient's blood. Factor XIII Concentrate (Human) is given to people whose blood is lacking Factor XIII. Factor XIII Concentrate (Human) works by assisting your blood in the usual clotting process, thereby preventing bleeding.

6 Sites

15 Participants

Recruiting

18 Years to 64 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Study Site

Dothan,Alabama,United States,36305

Study Site

Orange,California,United States,92868

Study Site

San Francisco,California,United States,94115

Study Site

Stockton,California,United States,95204

Study Site

Boston,Massachusetts,United States,02115

Study Site

Santa Cruz de Tenerife,Spain

Study Eligibility Criteria

Inclusion Criteria

* Written informed consent/assent for study participation obtained before undergoing any study-specific procedures
* Documented congenital FXIII deficiency that requires prophylactic treatment with a FXIII containing product.
* Males and females of any age with congenital FXIII deficiency.
* Received full hepatitis B vaccination and/or is hepatitis B surface antibody positive

Exclusion Criteria

* Diagnosis of acquired FXIII deficiency
* Administration of a FXIII-containing product, including blood transfusions or other blood products within 4 weeks prior to the planned Day 0
* Any known congenital or acquired coagulation disorder other than congenital FXIII deficiency
* Known or suspected to have antibodies towards FXIII
* Use of any other investigational medicinal product within 4 weeks prior to the Baseline Visit (Day 0)
* Positive result at screening for human immunodeficiency virus (HIV)
* Serum aspartate transaminase (AST) or serum alanine transaminase (ALT) concentration \>2.5 times the upper limit of normal
* Fibrinogen \< lower limit of normal
* Active bleeding
* Pregnant or breast-feeding
* Intention to become pregnant during the course of the study
* Female subjects of childbearing potential not using, or not willing to use, a medically reliable method of contraception for the entire duration of the study
* Surgical procedure anticipated during the study period
* Suspected inability (e.g., language problems) or unwillingness to comply with study procedures or history of noncompliance

Additional Studies

Additional studies can be found at ClinicalTrials.gov